Characteristic variations of serum alkaline DNase activity in relation to response to therapy and tumor prognosis in human lung cancer.
The objective of the present study was to evaluate serum alkaline DNase activity (SADA) variations as a useful means of lung cancer monitoring therapy. SADA was measured in 40 patients with non-small cell and small cell carcinomas. Blood samples were collected before (Time 0), during the treatment and months after therapy. A decrease in SADA during the first treatment indicates a good clinical response, whereas an absence of decrease indicates a non-response to treatment. In patients who respond to therapy, three types of variations of SADA are observed during the clinical course. A progressive regaining of SADA up to a value largely exceeding the level of the initial SADA value (T0) correlates with a complete remission. An incomplete regaining of enzyme activity corresponds to a partial remission, whereas no regaining of SADA precedes a fatal evolution. Such variations in SADA observed in the 40 patients with lung carcinomas support our previously published clinical results, confirming that the variations of SADA could be a reliable marker for the therapeutic monitoring of different human malignancies.
Economidou-Karaoglou
A
A
Unité de Biochimie Toxicologique et Cancérologique, Faculté de Médecine, Université de Louvain, Bruxelles, Belgium.
Opsomer
M
M
Petit
G
G
Lans
M
M
Taper
H S
HS
Roberfroid
M B
MB
D000368:Aged; D003131:Combined Modality Therapy; D003851:Deoxyribonucleases / Q000097:blood*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D011379:Prognosis
D003851:Deoxyribonucleases